US-based medical technology company BD (Becton, Dickinson and Company) has introduced its new haemodynamic monitoring platform, HemoSphere Alta.
HemoSphere Alta features AI-driven algorithms designed to assist clinicians in addressing blood pressure instability and optimise blood flow during critical procedures.
The platform advances BD’s smart connected care technologies to enhance patient outcomes and streamline clinical workflows.
HemoSphere is said to be BD’s most advanced haemodynamic monitoring technology and marks the first major product launch since the company’s acquisition of Advanced Patient Monitoring.
BD advanced patient monitoring president Tim Patz said: “HemoSphere Alta marks the latest milestone in our continuum of connected care innovations by redefining the clinician experience with more efficient workflows and increased usability.
“These AI-driven enhancements of advanced algorithms and machine learning provide clinicians with more insights and clinical decision support to help improve the quality of care for their patients.”
HemoSphere Alta introduces the Cerebral Autoregulation Index (CAI), a unique parameter that provides personalised insights into a patient’s blood pressure needs.
CAI is accessible through the non-invasive ForeSight IQ Sensor and the Acumen IQ Sensor, which connects to the patient’s arterial line.
In addition, the platform includes the Acumen Hypotension Prediction Index (HPI) software, which forecasts potential low blood pressure events.
Multiple large multicentre studies have shown that this feature reduces the depth, duration, and severity of hypotension, helping clinicians manage patient care.
Its monitor design, which includes a larger 15-inch high-resolution, customisable touchscreen display, split-screen views, and minimal disruptive pop-ups, aims to improve user experience.
Also, the voice and gesture command features enable hands-free interaction, maintaining sterility while allowing for easy operation, such as silencing alarms and switching views.
Northwestern University Feinberg School of Medicine department of anaesthesiology chairman Charles Hogue said: “Research over the past two decades has demonstrated the wide variability of the lower limit of cerebral blood flow autoregulation between individuals, as well as the risk for patient morbidity and mortality when blood pressure is maintained below this threshold.
“The availability of the novel Cerebral Autoregulation Index provides clinicians with a tool to detect conditions of impaired autoregulation and can help identify a patient’s lower limit of autoregulation.
“This, in combination with Hypotension Prediction Index technology and other advanced software and algorithms on the HemoSphere Alta platform allows us to both customise and predict patients’ low blood pressure.”
